**Activity Description**
Oncology nursing care is critical for the effective delivery of therapy in chronic lymphocytic leukemia (CLL), where the emergence of multiple novel agent classes, such as BTK and BCL-2 inhibitors, has transformed disease management. Furthermore, oncology nurses will play a key role in integrating the next wave of novel therapeutics, which range from newer BTK-based strategies to CAR-T cell therapy options. As always, nurses are perfectly placed to enhance modern CLL care by counseling patients on the benefits and risks of novel therapeutics across the spectrum of disease.

This “Clinical Consults” activity, developed in collaboration with the CLL Society, features nurse-to-nurse, case-based education designed to illustrate how nurses can decisively implement the latest recommendations for effective use of innovative therapeutics in CLL. The case-centric “Clinical Consult” segments will provide guidance on best practices for using first- and second-generation BTK inhibitor– and BCL-2 inhibitor–based regimens while preparing for the emergence of cellular therapy. Nurses remain the common thread linking informed CLL treatment decisions to improvement in patients—find out how during this educational session!

**Educational Objectives**

Upon completion of this activity, participants should be better able to:

* Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy
* Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes
* Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment